Maravai LifeSciences Holdings, Inc. (MRVI) News
Track canonical SquawkNews coverage tagged to MRVI, Maravai LifeSciences Holdings, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
MRVI maintained at neutral by UBS
UBS maintained Maravai LifeSciences at neutral on MRVI.
EQUITY | Sep 09, 2026, 06:02 PM UTC
M
Merck and Moderna report interim Phase 3 vaccine data hits endpoint
Merck and Moderna said interim Phase 3 data for Moderna’s personalized cancer vaccine met its primary endpoint, with Wells noting potential beneficiaries include RGEN, DHR, TMO and MRVI.
EQUITY | Aug 20, 2026, 01:25 PM UTC
L
MRVI Positive mRNA Cancer Vaccine Readout - Increases Visibility for Entire Life Science Sector and MRVI @ KEYB
MRVI Positive mRNA Cancer Vaccine Readout - Increases Visibility for Entire Life Science Sector and MRVI @ KEYB
EQUITY | Aug 20, 2026, 11:01 AM UTC
L
Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est
Maravai LifeSciences (NASDAQ: MRVI ) affirms FY2026 sales outlook from $205.000 million-$215.000 million to $205.000 million-$215.000 million vs $210.433 million estimate.
EARNINGS | Aug 06, 2026, 08:12 PM UTC
L
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued C
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP Protection in
GEOPOLITICS | Jul 20, 2026, 08:06 PM UTC